William Fisher Rosenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William Fisher Rosenberger has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Diane Uschner
George Mason University
5 shared publications- Sofia S. Villar
University of Cambridge
3 shared publications Yanying Wang
George Mason University
3 shared publications- Diane Uschner
Department of Biostatistics and Bioinformatics at the Biostatistics Center, George Washington University, Washington, DC 20052, USA
2 shared publications Feifang Hu
Department of Statistics George Washington University Washington, DC USA
2 shared publications- Lukas Pin
MRC Biostatistics Unit, University of Cambridge, UK
2 shared publications
Latest Publications
- Open Access
- 3 July 2025
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 81 (3)
Revisiting optimal allocations for binary responses: insights from considering type-I error rate control
This work revisits optimal response-adaptive designs from a type-I error rate perspective, highlighting when and how much these allocations exacerbate type-I error rate inflation—an issue previously undocumented. We explore a range of approaches from the literature that can be applied to reduce type-I error rate inflation. However, we found that all of these approaches fail to give a robust solution to the problem. To address this, we derive 2 optimal allocation proportions, incorporating the more robust score test (instead of the Wald test) with finite sample estimators (instead of the unknown true values) in the formulation of the optimization problem. One proportion optimizes statistical power, and the other minimizes the total number of failures in a trial while maintaining a fixed variance level. Through simulations based on an early phase and a confirmatory trial, we provide crucial practical insight into how these new optimal proportion designs can offer substantial patient outcomes advantages while controlling type-I error rate. While we focused on binary outcomes, the framework offers valuable insights that naturally extend to other outcome types, multi-armed trials, and alternative measures of interest.
- 3 July 2025
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 81 (3)
Open AccessRevisiting optimal allocations for binary responses: insights from considering type-I error rate control
This work revisits optimal response-adaptive designs from a type-I error rate perspective, highlighting when and how much these allocations exacerbate type-I error rate inflation—an issue previously undocumented. We explore a range of approaches from the literature that can be applied to reduce type-I error rate inflation. However, we found that all of these approaches fail to give a robust solution to the problem. To address this, we derive 2 optimal allocation proportions, incorporating the more robust score test (instead of the Wald test) with finite sample estimators (instead of the unknown true values) in the formulation of the optimization problem. One proportion optimizes statistical power, and the other minimizes the total number of failures in a trial while maintaining a fixed variance level. Through simulations based on an early phase and a confirmatory trial, we provide crucial practical insight into how these new optimal proportion designs can offer substantial patient outcomes advantages while controlling type-I error rate. While we focused on binary outcomes, the framework offers valuable insights that naturally extend to other outcome types, multi-armed trials, and alternative measures of interest.
- 3 March 2025
- Published by Springer Nature
- p. 477-482
CARA Randomization: Optimality, Inference, Enrichment
- 3 March 2025
- Published by Springer Nature
- p. 477-482
CARA Randomization: Optimality, Inference, Enrichment
- Open Access
- 14 August 2024
- Published by Springer Nature
- p. 313-339
Response-Adaptive Randomization Designs Based on Optimal Allocation Proportions
This book chapter discusses response-adaptive randomization procedures which are based on optimal allocation proportions, e.g. derived from theoretical optimization problems. We elucidate the objectives of these proportions, emphasizing their role in maximizing statistical power and/or enhancing patient benefit. Moreover, practical insights on estimation and targeting of these allocation proportions are provided. A clinical trial example, the CALISTO trial, illustrates the application of these procedures. We aim to provide an overview that serves as a basis for discussions about optimal allocation proportions, assists in their implementation in practice and highlights future research areas.
- 14 August 2024
- Published by Springer Nature
- p. 313-339
Open AccessResponse-Adaptive Randomization Designs Based on Optimal Allocation Proportions
This book chapter discusses response-adaptive randomization procedures which are based on optimal allocation proportions, e.g. derived from theoretical optimization problems. We elucidate the objectives of these proportions, emphasizing their role in maximizing statistical power and/or enhancing patient benefit. Moreover, practical insights on estimation and targeting of these allocation proportions are provided. A clinical trial example, the CALISTO trial, illustrates the application of these procedures. We aim to provide an overview that serves as a basis for discussions about optimal allocation proportions, assists in their implementation in practice and highlights future research areas.
- 27 November 2022
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 79 (3) , 2565-2576
Design Considerations for Two-Stage Enrichment Clinical Trials
When there is a predictive biomarker, enrichment can focus the clinical trial on a benefiting subpopulation. We describe a two-stage enrichment design, in which the first stage is designed to efficiently estimate a threshold and the second stage is a “phase III-like” trial on the enriched population. The goal of this paper is to explore design issues: sample size in Stages 1 and 2, and re-estimation of the Stage 2 sample size following Stage 1. By treating these as separate trials, we can gain insight into how the predictive nature of the biomarker specifically impacts the sample size. We also show that failure to adequately estimate the threshold can have disastrous consequences in the second stage. While any bivariate model could be used, we assume a continuous outcome and continuous biomarker, described by a bivariate normal model. The correlation coefficient between the outcome and biomarker is the key to understanding the behavior of the design, both for predictive and prognostic biomarkers. Through a series of simulations we illustrate the impact of model misspecification, consequences of poor threshold estimation, and requisite sample sizes that depend on the predictive nature of the biomarker. Such insight should be helpful in understanding and designing enrichment trials.
- 27 November 2022
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 79 (3) , 2565-2576
Design Considerations for Two-Stage Enrichment Clinical Trials
When there is a predictive biomarker, enrichment can focus the clinical trial on a benefiting subpopulation. We describe a two-stage enrichment design, in which the first stage is designed to efficiently estimate a threshold and the second stage is a “phase III-like” trial on the enriched population. The goal of this paper is to explore design issues: sample size in Stages 1 and 2, and re-estimation of the Stage 2 sample size following Stage 1. By treating these as separate trials, we can gain insight into how the predictive nature of the biomarker specifically impacts the sample size. We also show that failure to adequately estimate the threshold can have disastrous consequences in the second stage. While any bivariate model could be used, we assume a continuous outcome and continuous biomarker, described by a bivariate normal model. The correlation coefficient between the outcome and biomarker is the key to understanding the behavior of the design, both for predictive and prognostic biomarkers. Through a series of simulations we illustrate the impact of model misspecification, consequences of poor threshold estimation, and requisite sample sizes that depend on the predictive nature of the biomarker. Such insight should be helpful in understanding and designing enrichment trials.
- 20 July 2022
- Published by Springer Nature
- p. 855-874
Bias Control in Randomized Controlled Clinical Trials
- 20 July 2022
- Published by Springer Nature
- p. 855-874
Bias Control in Randomized Controlled Clinical Trials
- 2 July 2020
- Published by Taylor & Francis in Sequential Analysis
- Vol. 39 (3) , 295-306
Sequential design and analysis in the randomized clinical trial: A historical perspective
Sequential analysis, as invented by Wald, was not targeted to clinical trials; in fact, the randomized clinical trial was being invented nearly simultaneously by Hill on the other side of the Atlantic. The connection to clinical trials was established by Bross and Armitage in the early 1950s and applied in a number of trials during that decade. Restrictions in its applicability in practice led to a dry spell until its resurgence with group sequential methods. This article reviews the historical context of the use of sequential analysis in actual randomized clinical trials. It does not review methodological developments, except as they relate to the historical and philosophical setting.
- 2 July 2020
- Published by Taylor & Francis in Sequential Analysis
- Vol. 39 (3) , 295-306
Sequential design and analysis in the randomized clinical trial: A historical perspective
Sequential analysis, as invented by Wald, was not targeted to clinical trials; in fact, the randomized clinical trial was being invented nearly simultaneously by Hill on the other side of the Atlantic. The connection to clinical trials was established by Bross and Armitage in the early 1950s and applied in a number of trials during that decade. Restrictions in its applicability in practice led to a dry spell until its resurgence with group sequential methods. This article reviews the historical context of the use of sequential analysis in actual randomized clinical trials. It does not review methodological developments, except as they relate to the historical and philosophical setting.
- 3 June 2020
- Published by Wiley in Statistics in Medicine
- Vol. 39 (21) , 2843-2854
Randomization‐based interval estimation in randomized clinical trials
Randomization‐based interval estimation takes into account the particular randomization procedure in the analysis and preserves the confidence level even in the presence of heterogeneity. It is distinguished from population‐based confidence intervals with respect to three aspects: definition, computation, and interpretation. The article contributes to the discussion of how to construct a confidence interval for a treatment difference from randomization tests when analyzing data from randomized clinical trials. The discussion covers (i) the definition of a confidence interval for a treatment difference in randomization‐based inference, (ii) computational algorithms for efficiently approximating the endpoints of an interval, and (iii) evaluation of statistical properties (ie, coverage probability and interval length) of randomization‐based and population‐based confidence intervals under a selected set of randomization procedures when assuming heterogeneity in patient outcomes. The method is illustrated with a case study.
- 3 June 2020
- Published by Wiley in Statistics in Medicine
- Vol. 39 (21) , 2843-2854
Randomization‐based interval estimation in randomized clinical trials
Randomization‐based interval estimation takes into account the particular randomization procedure in the analysis and preserves the confidence level even in the presence of heterogeneity. It is distinguished from population‐based confidence intervals with respect to three aspects: definition, computation, and interpretation. The article contributes to the discussion of how to construct a confidence interval for a treatment difference from randomization tests when analyzing data from randomized clinical trials. The discussion covers (i) the definition of a confidence interval for a treatment difference in randomization‐based inference, (ii) computational algorithms for efficiently approximating the endpoints of an interval, and (iii) evaluation of statistical properties (ie, coverage probability and interval length) of randomization‐based and population‐based confidence intervals under a selected set of randomization procedures when assuming heterogeneity in patient outcomes. The method is illustrated with a case study.
- 17 December 2019
- Published by Wiley in Statistics in Medicine
- Vol. 39 (4) , 494-509
Randomization tests for multiarmed randomized clinical trials
We examine the use of randomization‐based inference for analyzing multiarmed randomized clinical trials, including the application of conditional randomization tests to multiple comparisons. The view is taken that the linkage of the statistical test to the experimental design (randomization procedure) should be recognized. A selected collection of randomization procedures generalized to multiarmed treatment allocation is summarized, and generalizations for two randomization procedures that heretofore were designed for only two treatments are developed. We explain the process of computing the randomization test and conditional randomization test via Monte Carlo simulation, developing an efficient algorithm that makes multiple comparisons possible that would not be possible using a standard algorithm, demonstrate the preservation of type I error rate, and explore the relationship of statistical power to the randomization procedure in the presence of a time trend and outliers. We distinguish between the interpretation of thep‐value in the randomization test and in the population test and verify that the randomization test can be approximated by the population test on some occasions. Data from two multiarmed clinical trials from the literature are reanalyzed to illustrate the methodology.
- 17 December 2019
- Published by Wiley in Statistics in Medicine
- Vol. 39 (4) , 494-509
Randomization tests for multiarmed randomized clinical trials
We examine the use of randomization‐based inference for analyzing multiarmed randomized clinical trials, including the application of conditional randomization tests to multiple comparisons. The view is taken that the linkage of the statistical test to the experimental design (randomization procedure) should be recognized. A selected collection of randomization procedures generalized to multiarmed treatment allocation is summarized, and generalizations for two randomization procedures that heretofore were designed for only two treatments are developed. We explain the process of computing the randomization test and conditional randomization test via Monte Carlo simulation, developing an efficient algorithm that makes multiple comparisons possible that would not be possible using a standard algorithm, demonstrate the preservation of type I error rate, and explore the relationship of statistical power to the randomization procedure in the presence of a time trend and outliers. We distinguish between the interpretation of thep‐value in the randomization test and in the population test and verify that the randomization test can be approximated by the population test on some occasions. Data from two multiarmed clinical trials from the literature are reanalyzed to illustrate the methodology.
- 14 October 2019
- Published by Springer Nature
- p. 1-20
Bias Control in Randomized Controlled Clinical Trials
- 14 October 2019
- Published by Springer Nature
- p. 1-20
Bias Control in Randomized Controlled Clinical Trials
- 1 January 2019
- Published by Springer Nature in Statistical Papers
- Vol. 60 (2) , 395-404
Randomization-based inference and the choice of randomization procedures
- 1 January 2019
- Published by Springer Nature in Statistical Papers
- Vol. 60 (2) , 395-404
Randomization-based inference and the choice of randomization procedures